Inventiva Extends Cash Runway to Mid-2027 After $172.5M U.S. Offering
Event summary
- Inventiva reported €99.3M in cash and cash equivalents as of December 31, 2025, with €131.6M in short-term deposits.
- 2025 revenues were €4.5M, down from €9.2M in 2024, primarily due to lower licensing revenues from CTTQ.
- Completed a $172.5M U.S. public offering in November 2025, raising €139.3M in net proceeds.
- Cash runway extended to mid-Q1 2027, with potential for mid-Q3 2027 if Tranche 3 warrants are fully exercised.
The big picture
Inventiva's strategic focus on MASH treatment with lanifibranor is critical as the company navigates a competitive biopharmaceutical landscape. The recent fundraising and extended cash runway provide a buffer, but execution in clinical trials and revenue diversification will be key to long-term viability. The company's ability to secure additional financing or milestone payments will be closely watched by investors.
What we're watching
- Clinical Trial Progress
- The pace at which Inventiva advances its NATiV3 Phase 3 trial for lanifibranor in MASH will determine its ability to meet regulatory milestones.
- Cash Burn Management
- Whether Inventiva can sustain its current cash burn rate while awaiting potential milestone payments and warrant exercises.
- Revenue Diversification
- How Inventiva plans to offset declining licensing revenues from CTTQ through other partnerships or product candidates.
Our editorial coverage: